Research has shown that BCL-2 expression is highly heterogeneous in DLBCL patients, and Venetoclax monotherapy consequently has poor efficacy in some RR-DLBCL patients, with an ORR of only 38% and a CR of 12% [96]. This evidence concerns the gene BCL2 and diffuse large B-cell lymphoma.